Spluttering US Generics Landscape Shows Signs Of Promise In Q2
Teva, Sandoz, Viatris Make Positive Noises In Q2 Readout
Executive Summary
High-value launches and an improving broader landscape for generic pricing provided a fillip for some US generics manufacturers in the second quarter, although others disclosed that they were still weathering the storm as the end of the year approaches.
You may also be interested in...
One Foot In The Door? Trio Look To Reenter Annulled EU Generic Tecfidera Market
A topsy-turvy legal battle going back some years led to a raft of Tecfidera generics being pulled from the market in December last year. Now, three of the affected companies are a step closer to reentering the market, which is set to remain a Tecfidera monopoly until February 2025.
Celltrion Eyes Near-Term Omalizumab Opportunity With CHMP Backing
The pool of prospective Xolair biosimilars is small, with only Teva and Kashiv BioSciences/Alvotech disclosing Phase III comparison trials for their biosimilar products. Ahead of them in the pack, Celltrion has just taken a giant stride towards the first pan-European marketing approval.
Sandoz Maintains Lead On Denosumab With First EU Recommendations
Sandoz has again demonstrated its clout in the biosimilars space, taking a major step towards obtaining pan-European marketing authorizations for its biosimilar Prolia/Xgeva products.